Discontinuation of infliximab therapy in patients with Crohn's disease in sustained complete remission (the STOP IT study): protocol for a double-blind, randomised, placebo-controlled, multicentre trial

INTRODUCTION: Infliximab (IFX), a monoclonal chimeric antibody against tumour necrosis factor (TNF) α, is effective for induction and maintenance of remission in moderate to severe Crohn's disease. Discontinuation of IFX maintenance therapy in patients in remission should be considered in order...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:BMJ Open
Huvudupphovsmän: Buhl, Sine Schnoor, Steenholdt, Casper, Brynskov, Jørn, Thomsen, Ole Østergaard, Bendtzen, Klaus, Ainsworth, Mark Andrew
Materialtyp: Artigo
Språk:Inglês
Publicerad: BMJ Publishing Group 2014
Ämnen:
Gastroenterology and Hepatology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4275671/
https://ncbi.nlm.nih.gov/pubmed/25524543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2014-005887
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk